Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KLK7 | P49862 | 2/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850898 | 0.91 | SYK (0.54) | SYKMAPTKLK7KLK5SIRT5 | |
| SCHEMBL4883932 | 0.83 | SYK (0.59) | SYKMAPTKLK7KLK5IDO1 | |
| SCHEMBL1022335 | 0.80 | SYK (0.53) | SYKMAPTKLK7KLK5SIRT5 | |
| SCHEMBL1022899 | 0.79 | SYK (0.67) | SYKMAPTKLK7KLK5IDO1 | |
| SCHEMBL20556459 | 0.79 | SYK (0.67) | SYKMAPTKLK7KLK5IDO1 | |
| SCHEMBL1021955 | 0.78 | SYK (0.64) | SYKMAPTKLK7KLK5IDO1 | |
| SCHEMBL20556374 | 0.77 | SYK (0.63) | SYKMAPTKLK7KLK5SIRT5 | |
| SCHEMBL19345775 | 0.77 | SYK (0.63) | SYKMAPTKLK7KLK5SIRT5 | |
| SCHEMBL20556328 | 0.77 | SYK (0.63) | SYKMAPTKLK7KLK5SIRT5 | |
| SCHEMBL4856702 | 0.77 | SYK (0.55) | SYKMAPTKLK7KLK5IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | SYK 3060/4885MAPT 4356/4885KLK7 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.